Clinical trial NCT04183530: The Individualized Accurate Diagnosis and Treatment of Chronic Objective Pulmonary Disease(COPD) Patients Based on Multidimensional Data
Official title: The Individualized Accurate Diagnosis and Treatment, as Well as the Prevention of Acute Exacerbation of Chronic Objective Pulmonary Disease(COPD) Based on Multidimensional Data
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Copd
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Lead sponsor: Wuhan Union Hospital, China
Sponsor class: OTHER
First posted: 2019-12-03
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: COPD patients and healthy people.

Brief summary: Chronic obstructive pulmonary disease (COPD) is known as progressive lung disease and the fourth leading cause of death worldwide. Despite valuable efforts, there is still no Individualized accurate diagnostic and prognostic tool for COPD. Hence, the investigators' research integrated multi-dimensional data of COPD patients, which may provide an invaluable bioinformatic resource for understanding the underlying molecular alterations that drive disease progression, with the goal of developing individualized accurate diagnostic and therapeutic inventions.

Detailed description: Chronic obstructive pulmonary disease (COPD) is known as progressive lung disease and the fourth leading cause of death worldwide. Acute exacerbations of COPD (AECOPD) is an important event of disease progression worsening in airway function and respiratory symptoms, bringing about respiratory failure, and increasing the rates of mortality. Despite valuable efforts, there is still no Individualized accurate diagnostic and prognostic tool for COPD. In this context, the investigators are to perform comprehensive transcriptomic, proteomic, metabonomic and exosome characterization of COPD patients and healthy controls. Biological samples of COPD participants, including blood, urine, stool, saliva, bronchoalveolar lavage fluid and clinical characteristics are going to be collected from the remaining materials of the routine clinical examination. And samples of healthy controls will be collected from the rest of the healthy examination practice. By integrating the multi-dimensional data, the investigators aim to elucidate the impact of molecular alterations driving phenotypic variation and to delineate the mechanisms of AECOPD for prospective exploration of personalized, precision-based clinical care.

Eligibility criteria: Inclusion Criteria:

1. Patient has signed informed consent.
2. Patients diagnosed with COPD or fully healthy participants.

Exclusion Criteria:

1. Tumor disease.
2. Heart disease.
3. Thyroid disease.

Primary outcomes:
measure: The transcriptome analysis of participates' serum or plasma
timeFrame: through study completion, an average of 1 year
measure: The metabolomics analysis of participates' urine or stool
timeFrame: through study completion, an average of 1 year
measure: The proteomics analysis of bronchoalveolar lavage fluid and saliva
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
state: Hubei
Study officials:
References: